Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055835
Status:
COMPLETED
Last Update Posted:
2013-01-31
First Post:
2003-03-06
Brief Title:
S0121 Neoadjuvant Carboplatin Paclitaxel and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Study Overview
Official Title:
Phase II Evaluation of Carboplatin Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as carboplatin paclitaxel gemcitabine and cisplatin work in different ways to stop tumor cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage tumor cells Giving chemotherapy before radiation therapy and combining chemotherapy with radiation therapy may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of neoadjuvant gemcitabine paclitaxel and carboplatin followed by cisplatin and radiation therapy in treating patients who have locally advanced or recurrent carcinoma cancer of the urothelium
PURPOSE Phase II trial to study the effectiveness of neoadjuvant gemcitabine paclitaxel and carboplatin followed by cisplatin and radiation therapy in treating patients who have locally advanced or recurrent carcinoma cancer of the urothelium
Detailed Description:
OBJECTIVES
Determine the overall survival of patients with locally advanced or recurrent carcinoma of the urothelium treated with neoadjuvant carboplatin paclitaxel and gemcitabine followed by concurrent cisplatin and radiotherapy
Determine the feasibility of administering this regimen to these patients
Determine the progression-free survival of patients treated with this regimen
Determine the qualitative and quantitative toxic effects of this regimen in these patients
Determine the response rate confirmed and unconfirmed of patients treated with the neoadjuvant regimen and those treated with the whole regimen
Determine the proportion of patients who qualify for concurrent cisplatin and radiotherapy after receiving the neoadjuvant regimen
Determine the potential value of suppressor gene expression analysis p53 and retinoblastoma gene and HER2 expression as indicators of prognosis andor response in patients treated with this regimen
OUTLINE This is a multicenter study
Patients receive neoadjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8 Treatment repeats every 21 days for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity
Within 4-8 weeks after the completion of neoadjuvant chemotherapy patients receive cisplatin IV over 30-60 minutes on day 1 Treatment repeats every 21 days for a maximum of 2 courses in the absence of disease progression or unacceptable toxicity Patients also undergo concurrent radiotherapy 5 days a week for 6 weeks
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 80 patients will be accrued for this study within 4 years
Determine the overall survival of patients with locally advanced or recurrent carcinoma of the urothelium treated with neoadjuvant carboplatin paclitaxel and gemcitabine followed by concurrent cisplatin and radiotherapy
Determine the feasibility of administering this regimen to these patients
Determine the progression-free survival of patients treated with this regimen
Determine the qualitative and quantitative toxic effects of this regimen in these patients
Determine the response rate confirmed and unconfirmed of patients treated with the neoadjuvant regimen and those treated with the whole regimen
Determine the proportion of patients who qualify for concurrent cisplatin and radiotherapy after receiving the neoadjuvant regimen
Determine the potential value of suppressor gene expression analysis p53 and retinoblastoma gene and HER2 expression as indicators of prognosis andor response in patients treated with this regimen
OUTLINE This is a multicenter study
Patients receive neoadjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8 Treatment repeats every 21 days for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity
Within 4-8 weeks after the completion of neoadjuvant chemotherapy patients receive cisplatin IV over 30-60 minutes on day 1 Treatment repeats every 21 days for a maximum of 2 courses in the absence of disease progression or unacceptable toxicity Patients also undergo concurrent radiotherapy 5 days a week for 6 weeks
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 80 patients will be accrued for this study within 4 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA032102 | NIH | SWOG | httpsreporternihgovquickSearchU10CA032102 |
| S0121 | OTHER | None | None |